RMD News and Press, ResMed Inc. From 10/26/23

2023-10-26 16:32:00 ET More on ResMed Here's The Price I'll Buy ResMed Stock ResMed - Trading Opportunity Now ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity ResMed Q1 2024 Earnings Preview ResMed upgraded at JPMorgan; says GLP-1 threa...

Year-over-year revenue grows 16% , operating profit up 5% , non-GAAP operating profit up 10% Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET ...

CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...

ResMed Inc. (RMD) is expected to report $1.63 for Q1 2024

2023-10-19 16:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-10-12 12:05:15 ET Summary FDA announcement of the creation of a Digital Health Advisory Committee causes a 7.2% decline in the iShares U.S. Medical Devices ETF. Digital health industry shows immense potential, driven by consumer-driven healthcare, remote monitoring, and teleh...

2023-10-11 10:59:46 ET More on iShares U.S. Medical Devices ETF IHI: Too Expensive Considering Long-Term Rate Uncertainty JPMorgan says time to buy MedTech based on past Seeking Alpha’s Quant Rating on iShares U.S. Medical Devices ETF Dividend scorecar...

2023-10-10 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-10-09 15:19:52 ET JPMorgan upgraded the respiratory device maker ResMed ( NYSE: RMD ) to Overweight from Neutral on Monday, arguing that the newer class of weight loss drugs called GLP-1 agonists will have only a modest impact on the company. Analyst David Low argues that t...

2023-10-06 11:25:33 ET Summary Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come ...